Market Cap 81.71M
Revenue (ttm) 49.22M
Net Income (ttm) -36.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -74.69%
Debt to Equity Ratio 0.58
Volume 21,314
Avg Vol 62,518
Day's Range N/A - N/A
Shares Out 55.58M
Stochastic %K 69%
Beta 2.92
Analysts Strong Sell
Price Target $5.60

Company Profile

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for t...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 1 81 69 16 00
Fax: 33 1 81 69 16 06
Address:
8 rue de la Croix Jarry, Paris, France
Bulltrader988
Bulltrader988 Jun. 20 at 7:25 PM
$CLLS still holding 👃👀
0 · Reply
Bullbullthara
Bullbullthara Jun. 20 at 7:18 PM
$CLLS looks like somebody knows something ... holding 24k let see what comes next week
0 · Reply
Bulltrader988
Bulltrader988 Jun. 14 at 7:22 PM
$CLLS reminder 👀👀
0 · Reply
4Reel
4Reel Jun. 12 at 9:02 PM
$CLLS cash is now at 2.5x market cap of 98m dollars. To go along with the AZ big pharm partnership that has been progressing. Revenues continuing to do well. Same potential as another cash rich company called $VTYX that was just under a dollar 2 months ago and is now 2.50ish. Always low volume but its time is coming this year imo. Question is when
0 · Reply
Bulltrader988
Bulltrader988 Jun. 7 at 6:08 PM
$CLLS 🤝🤝 $AZN $CLLS holding with $AZN 👃👀
0 · Reply
Bulltrader988
Bulltrader988 Jun. 5 at 9:19 PM
$CLLS 👀👀 https://www.stocktitan.net/news/CLLS/monthly-information-on-share-capital-and-company-voting-g5dshm0g3dw3.html
0 · Reply
rlkloehn
rlkloehn Jun. 4 at 3:29 PM
0 · Reply
rlkloehn
rlkloehn Jun. 4 at 3:28 PM
$CLLS Key findings: ✅ Pinpoint Accuracy: TALEN® with CssDNA ensures genes are inserted correctly in T-cells and stem cells (HSPCs), reducing risks of harmful DNA changes compared to viral methods. ✅ Healthier Cells: CssDNA supports better cell survival and long-term function in animal models, as shown by advanced techniques like CITE-seq, which analyzes cell behavior at a molecular level. ✅ Simpler and Scalable: Non-viral methods are easier to produce, paving the way for affordable, widely available therapies. This approach is like a GPS-guided tool, placing genetic fixes exactly where they’re needed while keeping cells healthy. It could be a step toward safer, more accessible treatments for patients worldwide. To know more about our research: file:///Users/pwilson/Downloads/A_0507_ASGCT2025_final-2.pdf
0 · Reply
rlkloehn
rlkloehn Jun. 4 at 3:28 PM
$CLLS 🧬 How to unlock safer gene therapies with non-viral technology? 🧬 Gene editing holds incredible promise for treating diseases like cancer, autoimmune disorders, and genetic conditions by precisely modifying disease-related genes. But traditional methods using viral vectors - tools that deliver new DNA into cells - face challenges, like inserting genes in unpredictable spots, which can harm cells, or complex manufacturing processes. Our research, presented at #ASGCT2025, explores a safer, more precise approach using TALEN® gene editing with non-viral single-stranded DNA (ssDNA). ✂️ Think of TALEN® as molecular scissors that cut DNA exactly where needed. Then, a circular ssDNA template (CssDNA) acts like a precise instruction manual, guiding new genetic material into that spot to restore or enhance cell functions - such as enabling immune cells to target cancer.
0 · Reply
mikefbi
mikefbi May. 27 at 4:53 PM
$CLLS Added not much due to low volume.
0 · Reply
Latest News on CLLS
Cellectis Reports Financial Results for the First Quarter 2025

May 12, 2025, 4:30 PM EDT - 6 weeks ago

Cellectis Reports Financial Results for the First Quarter 2025


Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript

Mar 14, 2025, 10:36 AM EDT - 3 months ago

Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript


Cellectis: Poised To Start Answering Questions In 2025

Dec 12, 2024, 3:08 PM EST - 6 months ago

Cellectis: Poised To Start Answering Questions In 2025


Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 1:59 PM EST - 8 months ago

Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript


Cellectis: Cheap With Promising But Speculative Cancer Therapies

Aug 30, 2024, 10:25 AM EDT - 10 months ago

Cellectis: Cheap With Promising But Speculative Cancer Therapies


Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

Aug 7, 2024, 2:00 AM EDT - 11 months ago

Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer


Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript

May 30, 2024, 2:06 PM EDT - 1 year ago

Cellectis S.A. (CLLS) Q1 2024 Earnings Call Transcript


Cellectis Reports Financial Results for First Quarter 2024

May 28, 2024, 4:30 PM EDT - 1 year ago

Cellectis Reports Financial Results for First Quarter 2024


Cellectis SA (CLLS) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 2:22 PM EST - 1 year ago

Cellectis SA (CLLS) Q3 2023 Earnings Call Transcript


Bulltrader988
Bulltrader988 Jun. 20 at 7:25 PM
$CLLS still holding 👃👀
0 · Reply
Bullbullthara
Bullbullthara Jun. 20 at 7:18 PM
$CLLS looks like somebody knows something ... holding 24k let see what comes next week
0 · Reply
Bulltrader988
Bulltrader988 Jun. 14 at 7:22 PM
$CLLS reminder 👀👀
0 · Reply
4Reel
4Reel Jun. 12 at 9:02 PM
$CLLS cash is now at 2.5x market cap of 98m dollars. To go along with the AZ big pharm partnership that has been progressing. Revenues continuing to do well. Same potential as another cash rich company called $VTYX that was just under a dollar 2 months ago and is now 2.50ish. Always low volume but its time is coming this year imo. Question is when
0 · Reply
Bulltrader988
Bulltrader988 Jun. 7 at 6:08 PM
$CLLS 🤝🤝 $AZN $CLLS holding with $AZN 👃👀
0 · Reply
Bulltrader988
Bulltrader988 Jun. 5 at 9:19 PM
$CLLS 👀👀 https://www.stocktitan.net/news/CLLS/monthly-information-on-share-capital-and-company-voting-g5dshm0g3dw3.html
0 · Reply
rlkloehn
rlkloehn Jun. 4 at 3:29 PM
0 · Reply
rlkloehn
rlkloehn Jun. 4 at 3:28 PM
$CLLS Key findings: ✅ Pinpoint Accuracy: TALEN® with CssDNA ensures genes are inserted correctly in T-cells and stem cells (HSPCs), reducing risks of harmful DNA changes compared to viral methods. ✅ Healthier Cells: CssDNA supports better cell survival and long-term function in animal models, as shown by advanced techniques like CITE-seq, which analyzes cell behavior at a molecular level. ✅ Simpler and Scalable: Non-viral methods are easier to produce, paving the way for affordable, widely available therapies. This approach is like a GPS-guided tool, placing genetic fixes exactly where they’re needed while keeping cells healthy. It could be a step toward safer, more accessible treatments for patients worldwide. To know more about our research: file:///Users/pwilson/Downloads/A_0507_ASGCT2025_final-2.pdf
0 · Reply
rlkloehn
rlkloehn Jun. 4 at 3:28 PM
$CLLS 🧬 How to unlock safer gene therapies with non-viral technology? 🧬 Gene editing holds incredible promise for treating diseases like cancer, autoimmune disorders, and genetic conditions by precisely modifying disease-related genes. But traditional methods using viral vectors - tools that deliver new DNA into cells - face challenges, like inserting genes in unpredictable spots, which can harm cells, or complex manufacturing processes. Our research, presented at #ASGCT2025, explores a safer, more precise approach using TALEN® gene editing with non-viral single-stranded DNA (ssDNA). ✂️ Think of TALEN® as molecular scissors that cut DNA exactly where needed. Then, a circular ssDNA template (CssDNA) acts like a precise instruction manual, guiding new genetic material into that spot to restore or enhance cell functions - such as enabling immune cells to target cancer.
0 · Reply
mikefbi
mikefbi May. 27 at 4:53 PM
$CLLS Added not much due to low volume.
0 · Reply
bruceleeboy
bruceleeboy May. 26 at 11:50 PM
$IMNPQ.DL0922 $MSCLF Satellos will likely do the 15:1 reverse split and drop OS to about 11M. Longs there may soon experience an Immune response. Timing is interesting. $NAYA/ $IVF and $CLLS have their annuals June 25th & 26th.
2 · Reply
mikefbi
mikefbi May. 22 at 9:23 PM
$CLLS Still
0 · Reply
Bulltrader988
Bulltrader988 May. 22 at 6:35 AM
$CLLS 👀👀 https://www.tipranks.com/news/company-announcements/cellectis-announces-board-change-and-key-shareholder-meeting-agenda?utm_source=webullapp.com&utm_medium=referral
0 · Reply
Bulltrader988
Bulltrader988 May. 21 at 9:18 PM
$CLLS 👀👀 https://www.stocktitan.net/news/CLLS/cellectis-annual-shareholders-general-meeting-to-be-held-on-june-26-dgyq8jmblde1.html
0 · Reply
PennyScam
PennyScam May. 20 at 1:40 PM
$CLLS Great news! Cellectis has $246 million in cash as of March 31, 2025, which is expected to provide runway into the second half of 2027.
1 · Reply
mikefbi
mikefbi May. 20 at 1:52 AM
$CLLS Still
0 · Reply
mikefbi
mikefbi May. 16 at 11:18 PM
$CLLS Going higher
1 · Reply
cyrve
cyrve May. 16 at 3:16 PM
$CLLS Q1 Analysis: https://findl.top/compare?q=md%2FTfFuqFq2T8VsO8LxgO%2BXryAEkH4y%2BYZW6AiCfq4KdOCVqBHd1OcSqVK6xfPTkAjn%2FiB5IfUYGXuZgFF4t0hf6h8oRWnbpLAWRkaAxiRI92JtcwS5djFM3aA5dzhSb7u1eASIsaQ9QfndawId4gr4gO0PVo78degnkdoqxVjzVXw064V9%2BMTcr3inyEWuv68g%2FJydKWehE9HkyeZ%2BqgyhPfVlVRoxLzkHKJ%2Fq0pcnhUrfHDWlDwtXCdwMY3v%2B3zT%2BinRzapMmFxpbsL7Y8SKC25KNVwRGx7MjbqPlZSZZhFrYADs5%2BABlFyEe%2FF1VcgIGsc5jTZjaPbcyBmNjvo8saqdh8IDNdTgXMuaSxcS%2F9B6WCRCCn&source=euronext&company=CELLECTIS++++++++++
0 · Reply
Bulltrader988
Bulltrader988 May. 15 at 3:55 PM
$CLLS 👀👀 https://seekingalpha.com/article/4787117-cellectis-stock-partnerships-promised-data-2025-continue-justify-buy?utm_source=webull.com&utm_medium=referral&feed_item_type=article
0 · Reply
Bulltrader988
Bulltrader988 May. 13 at 8:58 PM
$CLLS 👀👀
0 · Reply
rlkloehn
rlkloehn May. 13 at 8:26 PM
$CLLS Poster#2: High-fidelity C-to-T editing with basic editors Our TALE Base Editors (TALEB) is a revolutionary tool for precise DNA editing. TALEB converts cytosine (C) to thymine (T) without cutting DNA, offering a safer approach for future therapies. Main breakthroughs: ✅ Very efficient C-to-T editing: Our research optimizes TALAB's performance by refining target sequences and editor design, thus maximizing editing accuracy. ✅ Unparalleled specificity: Rigorous testing on primary T lymphocytes shows no detectable off-target changes, making TALEB a leading candidate for safe therapeutic applications. This innovation strengthens our gene editing toolkit, paving the way for transformative treatments for cancer, genetic disorders and beyond
1 · Reply
rlkloehn
rlkloehn May. 13 at 8:25 PM
$CLLS Poster #1: TALEN-® Insertion of non-viral transgenes for the advancement of cellular and gene therapies Our latest research combines TALEN®-mediated gene editing with the administration of non-viral single-stranded DNA (sbDNA) to advance safer and more effective treatments for diseases such as cancer, autoimmune diseases and genetic diseases. Main breakthroughs: ✅ Highly effective gene insertion into T cells and hematopoietic stem cells using linear and circular sbDNAs, improving cell viability and editing accuracy. ✅ Circular sbDNA surpasses viral vectors, preserving stem cell health and ensuring stable genetic modifications, as shown by transcriptomic analysis and in vivo studies. By overcoming challenges such as genomic toxicity and the manufacturing limits of traditional viral methods, our innovative approach offers effective and safe treatment options, transforming the future of patient care.
0 · Reply